Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Clinical trial NCT05577442 · UNKNOWN
Trial details
- NCT number
- NCT05577442
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-20
- Primary completion
- 2023-10-20
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.